Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer

Mark de Mol, Sabine Visser, Brenda L den Oudsten, Paul Lodder, Nico van Walree, Huub Belderbos, Joachim G Aerts^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

Fingerprint Dive into the research topics of 'Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer'. Together they form a unique fingerprint.